Belantamab mafodotin, positive headline results from the pivotal DREAMM-2 study for multiple myeloma
Positive results from the pivotal DREAMM-2 open-label, randomised study of two doses of Belantamab mafodotin ( GSK2857916 ) were announced.
The 196 patients in the trial had relapsed multiple myeloma, were refractory to an immunomodulatory drug, a proteasome inhibitor, and to treatment with an anti-CD38 antibody.
The two-arm study met its primary objective and demonstrated a clinically meaningful overall response rate with Belantamab mafodotin in the patient population.
The safety and tolerability profile was consistent with that observed in DREAMM-1, the first time in human study of Belantamab mafodotin.
Multiple myeloma is the second most common blood cancer and is generally considered treatable, but not curable.
Research into new therapies is needed as multiple myeloma commonly becomes refractory to available treatments.
The normal function of BCMA is to promote plasma cell survival by transduction of signals from two known ligands, BAFF ( B-cell activating factor ) and APRIL ( a proliferation-inducing ligand ).
This pathway has been shown to be important for myeloma cell growth and survival.
BCMA expression is limited to B cells at later stages of development.
BCMA is expressed at varying levels in myeloma patients and BCMA membrane expression is universally detected in myeloma cell lines.
Belantamab mafodotin is an immuno-conjugate comprising a humanised anti-B cell maturation antigen ( BCMA ) monoclonal antibody conjugated to the cytotoxic agent auristatin F via non-cleavable linker. ( Xagena )
Source: GSK, 2019